Calistoga Pharmaceuticals closes $40 million Series C financing Calistoga Pharmaceuticals.

Related StoriesOvarian cancer sufferers with a brief history of oral contraceptive make use of have better outcomesMeat-rich diet may increase kidney cancer riskMD Anderson study reveals why chemotherapy medicines not effective for many pancreatic cancers patientsCAL-101, the Company’s oral, delta selective PI3K inhibitor, offers demonstrated promising anti-tumor activity within a agent Phase 1 clinical trial involving more than 100 patients with hematologic malignancies. Results presented in June 2010 at the American Society of Clinical Oncology annual meeting demonstrated that one agent CAL-101 treatment in sufferers with relapsed or refractory indolent non-Hodgkin’s lymphoma , mantle cell lymphoma , and chronic lymphocytic leukemia led to overall response rates of 57 %, 67 % and thirty %, respectively.It is a single-middle, randomized, double-blind, placebo-controlled, one dose-escalation, first-in-human research of ARC-520 administered intravenously to healthy adult volunteers.01 mg/kg , 0.1 mg/kg , 0.3 mg/kg , 0.6 mg/kg , 1.2 mg/kg , and 2.0 mg/kg . The placebo group included 7 male and 5 female subjects with average of 28.1 +/ – 9.6 years. The treatment group included 12 male and 12 female topics with average age of 26.9 +/ – 6.7 years. Subjects were admitted to the unit overnight pre-dose and essential signs, telemetry, ECGs, safety labs, PK, and adverse events were monitored every day and night post-dose.